UBS AM’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.5M | Buy |
42,279
+9,497
| +29% | +$762K | ﹤0.01% | 1789 |
|
|
2026
Q1 | $2.52M | Buy |
32,782
+1,915
| +6% | +$149K | ﹤0.01% | 1929 |
|
|
2025
Q4 | $2.44M | Buy |
30,867
+1,201
| +4% | +$104K | ﹤0.01% | 1808 |
|
|
2025
Q3 | $2.72M | Sell |
29,666
-25,958
| -47% | -$2.12M | ﹤0.01% | 1627 |
|
|
2025
Q2 | $3.63M | Buy |
55,624
+7,302
| +15% | +$475K | ﹤0.01% | 1855 |
|
|
2025
Q1 | $3.24M | Buy |
48,322
+423
| +0.9% | +$25.3K | ﹤0.01% | 1778 |
|
|
2024
Q4 | $2.65M | Buy |
47,899
+13,948
| +41% | +$801K | ﹤0.01% | 1906 |
|
|
2024
Q3 | $2.03M | Sell |
33,951
-9,020
| -21% | -$550K | ﹤0.01% | 2027 |
|
|
2024
Q2 | $2.74M | Buy |
42,971
+27,435
| +177% | +$1.78M | ﹤0.01% | 1828 |
|
|
2024
Q1 | $1.07M | Hold |
15,536
| – | – | ﹤0.01% | 1974 |
|
|
2023
Q4 | $857K | Hold |
15,536
| – | – | ﹤0.01% | 2111 |
|
|
2023
Q3 | $902K | Buy |
15,536
+5,383
| +53% | +$311K | ﹤0.01% | 2007 |
|
|
2023
Q2 | $403K | Hold |
10,153
| – | – | ﹤0.01% | 2388 |
|
|
2023
Q1 | $403K | Buy |
10,153
+5,061
| +99% | +$213K | ﹤0.01% | 2388 |
|
|
2022
Q4 | $205K | Sell |
5,092
-1,393
| -21% | -$52.3K | ﹤0.01% | 2439 |
|
|
2022
Q3 | $208K | Sell |
6,485
-1,638
| -20% | -$56.1K | ﹤0.01% | 2598 |
|
|
2022
Q2 | $241K | Buy |
8,123
+514
| +7% | +$14.8K | ﹤0.01% | 2534 |
|
|
2022
Q1 | $214K | Hold |
7,609
| – | – | ﹤0.01% | 2665 |
|
|
2021
Q4 | $351K | Hold |
7,609
| – | – | ﹤0.01% | 2647 |
|
|
2021
Q3 | $250K | Hold |
7,609
| – | – | ﹤0.01% | 2656 |
|
|
2021
Q2 | $267K | Buy |
7,609
+827
| +12% | +$28.1K | ﹤0.01% | 2665 |
|
|
2021
Q1 | $245K | Buy |
+6,782
| New | +$212K | ﹤0.01% | 2528 |
|
|
2020
Q2 | – | Sell |
-5,746
| Closed | -$234K | – | 2466 |
|
|
2020
Q1 | $234K | Sell |
5,746
-267
| -4% | -$14.2K | ﹤0.01% | 2228 |
|
|
2019
Q4 | $371K | Sell |
6,013
-985
| -14% | -$65.3K | ﹤0.01% | 2326 |
|
|
2019
Q3 | $510K | Buy |
6,998
+1,552
| +28% | +$116K | ﹤0.01% | 2287 |
|
|
2019
Q2 | $448K | Buy |
5,446
+656
| +14% | +$46.7K | ﹤0.01% | 2260 |
|
|
2019
Q1 | $338K | Buy |
4,790
+3,948
| +469% | +$232K | ﹤0.01% | 2266 |
|
|
2018
Q4 | $37.9K | Buy |
+842
| New | +$44.1K | ﹤0.01% | 2586 |
|
|
2016
Q4 | – | Sell |
-4,700
| Closed | -$312K | – | 2505 |
|
|
2016
Q3 | $312K | Buy |
4,700
+300
| +7% | +$18.8K | ﹤0.01% | 2245 |
|
|
2016
Q2 | $246K | Buy |
+4,400
| New | +$214K | ﹤0.01% | 2321 |
|
|
2016
Q1 | – | Sell |
-4,800
| Closed | -$217K | – | 2629 |
|
|
2015
Q4 | $217K | Buy |
+4,800
| New | +$207K | ﹤0.01% | 2493 |
|
|
2015
Q3 | – | Sell |
-4,400
| Closed | -$273K | – | 2671 |
|
|
2015
Q2 | $273K | Buy |
+4,400
| New | +$262K | ﹤0.01% | 2422 |
|
Other funds holding ANIP
SCM
TCM
GACM
UBS AM's ANIP Position: Q2 2026 in Review
UBS AM increased its ANI Pharmaceuticals (ANIP) stake by 29% in Q2 2026, buying an estimated $762K and bringing the position to 42,279 shares worth $3.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1789.
UBS AM first reported a position in ANIP in Q2 2015 and has held it in 32 quarters since. The position peaked at $3.63M in Q2 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.
- UBS AM held 42,279 shares of ANI Pharmaceuticals worth $3.5M as of Q2 2026.
- UBS AM bought 9,497 ANI Pharmaceuticals shares in Q2 2026, an estimated $762K.
- ANI Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1789 holding.
- UBS AM first reported a position in ANI Pharmaceuticals in Q2 2015 and has held it in 32 quarters since.
- UBS AM's ANI Pharmaceuticals position peaked at $3.63M in Q2 2025.
- 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.